---
author: mike
pubDatetime: 2024-05-04 16:39:35.916000
modDatetime: 
title: Q124 ZTS earnings
slug: q124-zts-earnings
featured: false
ogImage: /assets/images/250_250.png
tags:
  - transcripts
  - earnings
  - pharmaceuticals
description: Earnings summary for Zoetis
---
## Q1 2024 Earnings Summary for Zoetis

### Business Performance

- Zoetis reported a strong Q1 2024 with 12% operational revenue growth and a 15% increase in adjusted net income operationally. 
- The U.S. market led with 16% growth, while international markets saw 8% operational growth. 
- Companion animal portfolio grew by 20% operationally, driven by demand for products like Librela, which saw a 189% operational increase globally. 
- Livestock products experienced a 1% operational decline. 

### Product Highlights

- Librela and Solensia, innovative treatments for osteoarthritis pain in dogs and cats, contributed significantly to growth. 
- Over 18 million doses of Librela and Solensia have been distributed worldwide. 
- Zoetis launched Bonqat, the first FDA-approved product to alleviate anxiety in cats, addressing an under-medicalized market segment. 

### Strategic Initiatives

- Zoetis continues to focus on innovation, having invested over $5 billion in R&D since its IPO, leading to more than 300 product lines. 
- Announced the sale of its global medicated feed additives and certain water-soluble product portfolios to Phibro Animal Health for $350 million, aiming to focus on areas with greater growth potential. 

### Financials

- Q1 2024 revenue was $2.2 billion, a 10% reported and 12% operational increase. Adjusted net income grew by 4% reported and 15% operationally. 
- Price growth was a significant contributor across all species, with hyperinflationary markets like Argentina boosting overall price growth by 2%. 
- Companion animal diagnostics portfolio declined by 12% operationally due to a distribution model change in the U.S. 
- Livestock portfolio declined by 1% operationally, impacted by economic conditions in China and other market challenges. 

### Forward-Looking Statements

- Zoetis raised its 2024 operational guidance, reflecting confidence in the resilience of the animal health market and the execution of strategic growth priorities. 
- Revenue expectations for 2024 are between $9.05 billion and $9.20 billion, representing 8.5% to 10.5% operational growth. 
- Adjusted net income for 2024 is projected to be in the range of $2.62 billion to $2.67 billion, indicating operational growth of 13% to 15%. 

### Market Leadership and Innovation

- Zoetis highlighted its leadership in creating new markets through innovation, particularly in parasiticides, dermatology, and now osteoarthritis pain treatment, expanding the overall industry opportunity. 
- The company's strategic focus on innovative solutions continues to drive growth and market expansion